Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

Abstract Background CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy has shown remarkable efficacy in treating relapsed or refractory pediatric B-lineage acute lymphoblastic leukemia (B-ALL). However, poor results are obtained when the same product is reused in patients who relapse aft...

Full description

Bibliographic Details
Main Authors:	Wenjie Li, Lixia Ding, Wenhua Shi, Xinyu Wan, Xiaomin Yang, Jing Yang, Tianyi Wang, Lili Song, Xiang Wang, Yani Ma, Chengjuan Luo, Jingyan Tang, Longjun Gu, Jing Chen, Jun Lu, Yanjing Tang, Benshang Li
Format:	Article
Language:	English
Published:	BMC 2023-03-01
Series:	Journal of Translational Medicine
Subjects:	B-ALL Second CAR-T Co-administration CD19/CD22 CAR-T
Online Access:	https://doi.org/10.1186/s12967-023-04019-4

Similar Items

A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
by: Yu Zhang, et al.
Published: (2022-03-01)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
by: Hanren Dai, et al.
Published: (2020-04-01)

Increased Activity of a NK-Specific CAR-NK Framework Targeting CD3 and CD5 for T-Cell Leukemias
by: Elisaveta Voynova, et al.
Published: (2022-01-01)

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
by: Nathan J. Fergusson, et al.
Published: (2023-04-01)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
by: Lihe Su, et al.
Published: (2022-12-01)

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
by: Yuan Meng, et al.
Published: (2021-06-01)

Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality
by: Richard Smith, et al.
Published: (2023-07-01)

Targeting CD22 for B-cell hematologic malignancies
by: Jia Xu, et al.
Published: (2023-10-01)

Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR)
by: Nicola Mitwasi, et al.
Published: (2022-04-01)

Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis
by: Ahmed Abbasi, et al.
Published: (2020-01-01)

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
by: Simon Loff, et al.
Published: (2020-06-01)

A novel multimeric sCD19‐streptavidin fusion protein for functional detection and selective expansion of CD19‐targeted CAR‐T cells
by: Hui Lian, et al.
Published: (2022-08-01)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
by: Xiaopeng Tian, et al.
Published: (2023-04-01)

Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma
by: Vita Golubovskaya, et al.
Published: (2021-02-01)

Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy
by: Tahir Zaib, et al.
Published: (2023-01-01)

Enrichment of T-cell proliferation and memory gene signatures of CD79A/CD40 costimulatory domain potentiates CD19CAR-T cell functions
by: Socheatraksmey Ung, et al.
Published: (2022-11-01)

CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19<sup>+</sup>HLA-C1<sup>−</sup> Malignant B Cells While Sparing CD19<sup>+</sup>HLA-C1<sup>+</sup> Healthy B Cells
by: Lei Tao, et al.
Published: (2020-09-01)

CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement
by: Antonia Maria S. Müller, et al.
Published: (2019-09-01)

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
by: Zhitao Ying, et al.
Published: (2021-02-01)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
by: YuanBo Xue, et al.
Published: (2021-02-01)

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
by: Xinjie Xu, et al.
Published: (2019-11-01)

The Mechanisms of Altered Blood–Brain Barrier Permeability in CD19 CAR T–Cell Recipients
by: Soniya N. Pinto, et al.
Published: (2024-01-01)

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
by: Wei Sang, et al.
Published: (2020-08-01)

Complications after CD19+ CAR T-Cell Therapy
by: Olaf Penack, et al.
Published: (2020-11-01)

Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis
by: Han Xu, et al.
Published: (2024-04-01)

Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology
by: Konstantinos Lontos, et al.
Published: (2022-12-01)

Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients
by: Cihan Taştan, et al.
Published: (2020-11-01)

CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models
by: Andrea Timpanaro, et al.
Published: (2023-11-01)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
by: Leonardo M. R. Ferreira, et al.
Published: (2021-11-01)

Getting CD19 Into Shape: Expression of Natively Folded “Difficult-to- Express” CD19 for Staining and Stimulation of CAR-T Cells
by: Elisabeth Lobner, et al.
Published: (2020-02-01)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
by: Yun Liang, et al.
Published: (2021-02-01)

Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer
by: Martin J. Raftery, et al.
Published: (2023-05-01)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
by: Heng Mei, et al.
Published: (2021-10-01)

CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
by: Tingdang Liu, et al.
Published: (2023-10-01)

CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment
by: Dasom Kong, et al.
Published: (2024-05-01)

Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells
by: Jia Feng, et al.
Published: (2022-09-01)

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy
by: Yuanyuan Liu, et al.
Published: (2022-10-01)

Most Do, but Some Do Not: CD4+CD25− T Cells, but Not CD4+CD25+ Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR)
by: Andreas A. Hombach, et al.
Published: (2017-08-01)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
by: Hejin Jia, et al.
Published: (2019-06-01)

Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
by: Lili Li, et al.
Published: (2022-12-01)